HHS Peptide Policy Explained: BPC-157, TB-500 & 4 More (Comments Close Nov 13)
HHS will allow 503A pharmacies to compound six peptides under strict conditions. Here's what it means for research-use vendors, the COA bar, and how to comment by Nov 13.
PepAssure team
Editorial note: PepAssure covers peptides for research use only. This article explains a federal policy. It is not medical, dosing, or legal advice.
The short answer
On October 28, 2026, the U.S. Department of Health and Human Services (HHS) announced that it will not take enforcement action against licensed compounding pharmacies, federal facilities, and licensed physicians that compound six peptides: BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. They must meet a strict list of conditions. None of the six peptides is FDA-approved, none has been added to FDA's 503A bulks list, and its conditions require API from an FDA-registered manufacturer, so research-use-only material doesn't qualify. Public comments close at 11:59 PM Eastern on Friday, November 13, 2026.
What HHS announced
- •Agency: the HHS Office of the Secretary, not FDA. The notice is signed by Secretary Robert F. Kennedy Jr.
- •Document: "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances"
- •Federal Register: FR Doc. 2026-22192, 91 FR 68526–68527, published October 30, 2026. It was filed for public inspection on October 28, 2026 at 11:15 AM. (Federal Register · govinfo text)
- •Docket: HHS-OASH-2026-0496, RIN 0910-ZD94
- •Status: the Federal Register notice describes the document as a draft policy and invites comments; HHS says to use its website for the most current version.
The notice says HHS sees "significant interest in the use of these peptides in compounding given the lack of availability of approved products." To "expand and improve patient access," it says it does not intend to take enforcement action against compounders using the listed peptides. (Federal Register)
The six peptides and their scope
The policy's Appendix B ties each peptide to a specific form and route. These are listed here only to show the policy's scope. They are not usage guidance. (policy text, HHS; Holland & Knight summary)
| Peptide (form in policy) | Scope listed in Appendix B |
|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral and topical dosage forms |
| TB-500 acetate | Subcutaneous or intramuscular injectable dosage forms |
| Epitalon acetate | Subcutaneous or intramuscular injectable, dispensed in intermittent courses |
| Semax (free base) | Intranasal |
| KPV acetate | Topical and oral dosage forms |
| MOTS-c acetate | Subcutaneous or intramuscular injectable dosage forms |
Enforcement discretion vs. approval vs. the 503A bulks list
These three things are often confused.
- •FDA approval means FDA reviewed a drug's safety and effectiveness. None of the six peptides has it. The notice itself says compounded drugs "are not FDA-approved."
- •The 503A bulks list (21 CFR 216.23) is the formal list of ingredients that compounding pharmacies may use when no USP monograph or approved drug covers them. FDA adds substances through notice-and-comment rulemaking. These six have not been added. The notice says only that "FDA's future rulemakings may propose adding some or all of these peptides."
- •Enforcement discretion is what HHS actually did. It is a statement that HHS does not intend to act against compounders that meet the conditions. The notice says it "does not establish any rights for any person and is not binding on HHS or the public," and that HHS may revisit it "if, among other things, a safety signal or product quality issue arises." (Federal Register)
In short, the policy is interim, conditional, and revocable.
The 10 conditions, in brief
HHS's discretion applies only when all of the following are met. The summary below follows the policy text and Holland & Knight's and BakerHostetler's analyses.
- Interim access list. The peptide is in Appendix A.
- Identity. It matches Appendix B's sequence, structure, molecular weight, formula, and route limits.
- Characterization. It comes from an FDA-registered facility with a valid certificate of analysis (COA). The COA must show identity, purity, potency, and the absence of harmful contaminants "such as endotoxins, heavy metals, microbial contamination, and impurities."
- Original manufacturer. The original maker, not a repacker or distributor, must be FDA-registered and CGMP-compliant, and its facility location must appear on the COA. Resellers must document that they validated the manufacturer and its COA.
- Reporting. Serious adverse events and quality issues are reported to FDA's MedWatch and to the relevant states.
- Labeling. The label must say "This is a compounded drug product. Not for resale."
- Single API. The product contains only one listed peptide.
- Oral forms. Oral products need documented bioavailability.
- Devices. The only co-packaged device is an FDA 510(k)-cleared syringe.
- Everything else. All other FDCA and 503A rules still apply, including a valid patient-specific prescription, sanitary conditions, and state pharmacy board rules.
Conditions 3 and 4 matter most for buyers. They set the documentation standard HHS expects for peptide material.
What this means for research-use-only vendors and buyers
The policy offers nothing to research-use-only (RUO) sellers. It applies only to 503A compounders, and it requires material from an FDA-registered, CGMP-compliant original manufacturer. Holland & Knight notes that the policy "does not extend to research-use-only API," and BakerHostetler says it does not apply to products sold as research chemicals.
HHS also says plainly why it acted. The policy text states:
"The Secretary of HHS has determined that this limited enforcement-discretion policy will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients."
— HHS policy, "HHS Interim Enforcement Policy" section (HHS policy text)
The policy creates a pharmacy pathway and says outright that its goal is to pull demand away from the RUO market. It creates no new protection for research vendors. Their legal position is the same as it was on October 27.
Will RUO vendors face more enforcement?
The policy does not announce any enforcement action against research vendors. As of November 5, 2026, we found no FDA, DOJ or HHS enforcement action involving these six peptides announced since the October 28 policy. For actions already on record, see PepAssure's Enforcement Watch and our roundup of peptide vendor shutdowns and enforcement, 2024–2026.
Use the policy's COA bar to check any COA
Research vendors are not bound by condition 3, but it is a useful benchmark. Check any COA you are handed against this list:
- •Identity: Does the COA confirm the sequence or structure with a method such as mass spectrometry, and does the molecular weight match?
- •Purity: Is an HPLC purity figure reported, with the chromatogram attached?
- •Potency/content: Is the measured amount reported, not just the labeled amount?
- •Endotoxins: Is there an endotoxin result?
- •Heavy metals: Tested or not?
- •Microbial contamination: Tested or not?
- •Impurities: Are related impurities listed?
- •Traceability: Does the COA name the testing lab and lot number? HHS's condition 4 also asks for the original manufacturer's facility location.
Most research COAs cover only identity and purity. That doesn't make a vendor bad, but it is less than what HHS asks of pharmacy suppliers. Upload a COA to PepAssure's COA verifier to check that it's authentic, and see how to read a peptide COA for a line-by-line walkthrough.
Where the six peptides stand on PepAssure
For research buyers comparing vendors, here are PepAssure's independent rankings, COA records, and live pricing for each peptide:
- •BPC-157: best BPC-157 vendors.
- •TB-500: best TB-500 vendors.
- •KPV: KPV vendors, purity, COA & price.
- •MOTS-c: best MOTS-c vendors.
- •Epitalon: best Epitalon vendors.
- •Semax: best Semax vendors.
Rankings update as new lab results arrive. As of November 5, 2026, PepAssure's records include 30 independent (third-party) COAs across these six peptides. To compare current prices, use live pricing.
How to comment before November 13
Anyone can comment. Here's how:
- Go to the docket on Regulations.gov: HHS-OASH-2026-0496, or comment directly at regulations.gov/commenton/HHS-OASH-2026-0496-0002.
- Select Comment on the policy document.
- Write your comment. You can attach files.
- Submit by 11:59 PM Eastern, Friday, Nov 13, 2026 (9:59 PM in Arizona). The docket shows late comments are not accepted.
Comments are posted publicly, so leave out personal details you don't want published. HHS says comments "may provide additional evidence that FDA can consider in rulemaking." FDA's rule at 21 CFR 216.23 weighs four factors for each substance: its physical and chemical characterization, safety, any evidence of effectiveness, and its history of use in compounding (Peptide Policy Watch). Comments backed by data tend to carry more weight. PepAssure takes no position on what you should say.
What happens next
- •FDA rulemaking on the 503A bulks list decides whether these peptides become formally eligible for compounding. HHS says FDA "may propose adding some or all" of them.
- •State boards of pharmacy still regulate compounding. The policy covers only federal enforcement and doesn't override state law.
- •Revisions: HHS can narrow or withdraw the policy if safety or quality problems appear.
PepAssure will update this page and our 2026 regulatory landscape guide as things change.
Timeline
- •Sept 2023: BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax are placed in FDA's Category 2 (Sept 29, 2023 for TB-500, Epitalon, Semax and MOTS-c, per the policy's Appendix B).
- •Apr 22, 2026: they are removed from Category 2. Per Appendix B, "neither the placement nor the removal changed" their 503A status.
- •July 23–24, 2026: FDA's Pharmacy Compounding Advisory Committee meets and votes in favor of listing the six peptides (FDA meeting page). FDA's drug center (CDER) had recommended against listing them (Appendix B).
- •Oct 14, 2026: the White House Office of Management and Budget (OIRA) receives the "Interim Access Policy for Compounding Using Certain Peptides" for review; OIRA concludes review on Oct 27 (reginfo.gov).
- •Oct 28, 2026: HHS announces the policy, and it is filed for public inspection.
- •Oct 30, 2026: published in the Federal Register.
- •Nov 13, 2026, 11:59 PM ET: the comment period closes.
FAQ
Is BPC-157 legal now after the HHS policy?
No peptide was approved. In a notice published in the Federal Register on October 30, 2026 (FR Doc 2026-22192, docket HHS-OASH-2026-0496), HHS said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, TB-500, KPV, MOTS-c, Epitalon or Semax under section 503A, provided they meet all of the policy's conditions. The policy is interim and non-binding, does not add these peptides to FDA's 503A bulks list, and its conditions, including API from an FDA-registered manufacturer with a valid COA, mean research-use-only material doesn't qualify.
What does the HHS peptide policy change for research-use-only vendors?
Directly, nothing protects them. The policy covers only qualifying 503A compounders, and it requires API from an FDA-registered, CGMP-compliant original manufacturer with a full COA. That rules out research-use-only sourcing. HHS describes the policy as a way to discourage use of research-use-only peptides from foreign manufacturers, so research buyers should expect closer scrutiny of that market rather than a new legal pathway.
How do I comment on the HHS peptide policy, and when is the deadline?
Submit a written comment at regulations.gov on docket HHS-OASH-2026-0496. The docket lists a close of 11:59 PM Eastern on Friday, November 13, 2026 (9:59 PM Arizona time), and late comments are not accepted. Comments are public. HHS says they may provide evidence FDA can consider in later rulemaking on whether to add these peptides to the 503A bulks list.
Are these peptides FDA approved?
No. Products compounded under the policy remain unapproved drugs.
Does the policy override state law?
No. It covers only federal enforcement. State boards of pharmacy can still restrict or condition compounding of these peptides.
Sources checked November 5, 2026. PepAssure is independent and free. We don't sell peptides.
Related Articles
Peptide vendors that shut down or faced enforcement, 2024–2026: the record
Thirteen research-peptide vendors with a government enforcement record or a reported closure, in date order, each with its source. What the record says, what it does not, and what to do if you bought from one.
2026 Peptide Regulatory Landscape: What Researchers Need to Know
A factual overview of the current regulatory environment for research peptides in the US, EU, and key international markets — and what's changing.